# Enspryng

NDC: 50242-005
Generic name: Satralizumab
Labeler / Manufacturer: Genentech, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: SUBCUTANEOUS
Marketing started: 20261015

FDA application: BLA761149

## Active ingredients

- SATRALIZUMAB: 180 mg/1.5mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"50242-005"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=50242-005